Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide) and dual GLP-1/GIP agonists (tirzepatide) produce clinically significant weight loss (10-21%) and reduce obesity-related cardiovascular and metabolic complications.
If you have obesity, newer GLP-1 or GLP-1/GIP medications (like semaglutide or tirzepatide) are highly effective, often producing 15-20% weight loss when combined with lifestyle changes. These drugs also significantly improve cardiovascular risk factors. Discuss these options with your doctor, especially if you have a BMI over 30 (or 27 with health issues).
Recently developed drugs and those currently under development have been shown to reduce body weight by more than 10% and are expected to reduce obesity-related complications.
Why this rating
Supported by multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (STEP, SURMOUNT, SCALE).
Source
An Overview of Existing and Emerging Weight-Loss Drugs to Target Obesity-Related Complications: Insights from Clinical Trials
Mi-Kyung Kim et al. · Biomolecules & Therapeutics · 2024
DOI 10.4062/biomolther.2024.228
More from this paper
- Tirzepatide, a dual GLP-1/GIP receptor agonist, produces greater weight loss (up to 21%) and superior body composition changes compared to other anti-obesity medications.Strong
- Older anti-obesity medications (orlistat, naltrexone/bupropion, phentermine/topiramate) produce modest weight loss (5-11%) and are less effective than newer GLP-1/GIP agonists.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →